AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
139_CD
IFRS_NN
Restatements_NOMZ
Introduction_NOMZ
to_TO
be_VB [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
,_,
as_RB
is_VPRT
payments_NOMZ
and_PHC
milestones_NN
,_,
are_VPRT [PASS]
capitalized_VBN
AstraZeneca_NN
currently_RB
prepares_VPRT
its_PIT
primary_JJ
required_VBN [SUAV]
under_IN
FRS_NN
17_CD
Retirement_NOMZ
and_CC
amortised_VBN
over_IN
their_TPP3
economic_JJ
lives_NN
from_PIN
financial_JJ
statements_NOMZ
under_IN
UK_NN
Generally_RB
Benefits_NN
._.
Intangible_JJ
assets_NN
relating_VBG [WZPRES]
to_PIN
products_NN
Accepted_JJ
Accounting_GER
Principles_NN
UK_NN
GAAP_NN
._.
endorsed_VBN [PASTP]
by_PIN
the_DT
EU_NN
,_,
will_PRMD
be_VB [BEMA]
effective_PRED
for_PIN
in_PIN
development_NOMZ
both_DT
internally_RB
generated_VBN
From_PIN
2005_CD
onwards_NN
the_DT
Group_NN
will_PRMD
be_VB
accounting_VBG
periods_NN
commencing_VBG [WZPRES]
on_PIN
or_CC
and_CC
externally_RB
acquired_VBN
are_VPRT [BEMA]
subject_PRED
to_TO
required_VBN [SUAV]
to_TO
prepare_VB
its_PIT
consolidated_JJ
financial_JJ
after_IN
1_CD
January_NN
2006_CD
,_,
with_PIN
earlier_TIME
impairment_NOMZ
testing_GER
at_PIN
each_QUAN
balance_NN
sheet_NN
statements_NOMZ
in_PIN
accordance_NN
with_PIN
International_NN
adoption_NOMZ
encouraged_VBN [WZPAST]
by_PIN
the_DT
IASB_NN
._.
date_NN
or_CC
earlier_TIME
upon_PIN
indication_NOMZ
of_PIN
impairment_NOMZ
._.
Accounting_GER
Standards_NN
IAS_NN
and_PHC
International_NN
AstraZeneca_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
provisions_NN
Any_QUAN
impairment_NOMZ
losses_NN
are_VPRT [PASS]
written_VBN [PUBV]
off_PIN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
as_IN
of_PIN
this_DEMO
amendment_NOMZ
in_PIN
its_PIT
restated_VBN
immediately_TIME
to_PIN
income_NN
._.
adopted_VBN [PASTP]
by_PIN
the_DT
European_NN
Union_NN
EU_NN
._.
change_NN
applies_VPRT
to_PIN
all_QUAN
financial_JJ
reporting_GER
for_PIN
IFRS_NN
2_CD
,_,
IFRS_NN
6_CD
and_CC
various_JJ
IFRIC_NN
Business_NOMZ
combinations_NOMZ
and_PHC
goodwill_NN
accounting_GER
periods_NN
beginning_VBG [WZPRES]
on_PIN
or_CC
after_IN
interpretations_NOMZ
and_PHC
amendments_NOMZ
to_PIN
On_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
fair_JJ
values_NN
1_CD
January_NN
2005_CD
and_CC
,_,
consequently_CONJ
,_,
SIC_NN
12_CD
have_VPRT [PEAS]
not_XX0
yet_RB
been_VBN [PASS]
endorsed_VBN
._.
are_VPRT [PASS]
attributed_VBN
to_PIN
the_DT
net_JJ
assets_NN
acquired_VBN
._.
AstraZenecas_NN
first_JJ
IFRS_NN
results_NN
will_PRMD
be_VB [BEMA]
its_PIT
Goodwill_NN
arises_VPRT
where_RB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
interim_JJ
results_NN
for_PIN
Q1_NN
2005_CD
._.
The_DT
Groups_NN
first_JJ
Accounting_GER
policies_NN
consideration_NOMZ
given_VBN [WZPAST]
for_PIN
a_DT
business_NOMZ
exceeds_VPRT
Annual_JJ
Report_NN
under_IN
IFRS_NN
will_PRMD
be_VB [BEMA]
for_PIN
2005_CD
._.
the_DT
fair_JJ
value_NN
of_PIN
such_JJ
net_JJ
assets_NN
._.
As_IN
the_DT
Group_NN
publishes_VPRT
comparative_JJ
Basis_NN
of_PIN
accounting_VBG
information_NOMZ
for_PIN
two_CD
years_NN
in_PIN
its_PIT
Annual_JJ
As_IN
set_VBN
out_PIN
in_PIN
the_DT
Basis_NN
of_PIN
Preparation_NOMZ
,_,
the_DT
Goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
is_VPRT [PASS]
capitalized_VBN
Report_NN
,_,
the_DT
date_NN
for_PIN
transition_NOMZ
to_PIN
IFRS_NN
is_VPRT [PASS]
restated_VBN
financial_JJ
information_NOMZ
on_PIN
pages_NN
139_CD
and_CC
subject_JJ
to_PIN
impairment_NOMZ
review_NN
,_,
both_DT
1_CD
January_NN
2003_CD
,_,
this_DEMP
being_VBG [BEMA]
the_DT
start_NN
of_PIN
the_DT
to_PIN
146_CD
,_,
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
in_PIN
accordance_NN
annually_RB
and_ANDC
when_RB
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
earliest_JJ
period_NN
of_PIN
comparative_JJ
information_NOMZ
._.
with_PIN
IAS_NN
and_PHC
IFRS_NN
as_IN
adopted_VBN
by_PIN
the_DT
EU_NN
._.
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
Prior_RB
to_PIN
1_CD
January_NN
2003_CD
,_,
goodwill_NN
was_VBD
To_TO
explain_VB [PUBV]
how_RB [WHCL]
AstraZenecas_NN
reported_VBD [PUBV]
The_DT
accounting_GER
policy_NN
for_PIN
financial_JJ
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
:_:
such_JJ
performance_NN
and_CC
financial_JJ
position_NOMZ
are_VPRT
instruments_NOMZ
complies_NN
with_PIN
the_DT
EU_NN
carve_VB
out_PIN
amortisation_NOMZ
ceased_VBD
on_PIN
31_CD
December_NN
2002_CD
._.
affected_VBN [PASTP]
by_PIN
this_DEMO
change_NN
,_,
information_NOMZ
version_NN
of_PIN
IAS_NN
39_CD
._.
The_DT
policies_NN
also_RB
assume_VPRT [PRIV]
previously_TIME
published_VBN
under_IN
UK_NN
GAAP_NN
is_VPRT
that_DEMO
the_DT
amendments_NOMZ
to_PIN
IAS_NN
19_CD
Employee_NN
The_DT
Groups_NN
policy_NN
up_IN
to_TO
and_CC
including_VBG
1997_CD
restated_VBN
under_IN
IFRS_NN
on_PIN
pages_NN
139_CD
to_PIN
146_CD
._.
Benefits_NN
published_VBN [WZPAST]
in_PIN
December_NN
2004_CD
by_PIN
the_DT
was_VBD
to_TO
eliminate_VB
goodwill_NN
arising_VBG [WZPRES]
upon_PIN
IASB_NN
,_,
allowing_VBG [SUAV]
actuarial_JJ
gains_NN
and_PHC
losses_NN
to_PIN
acquisitions_NOMZ
against_PIN
reserves_NN
._.
Under_IN
IFRS_NN
1_CD
As_IN
noted_VBN [PRIV]
below_PLACE
,_,
these_DEMO
financial_JJ
statements_NOMZ
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
through_PIN
reserves_NN
,_,
will_PRMD
be_VB
and_PHC
IFRS_VB
3_CD
,_,
such_JJ
goodwill_NN
will_PRMD
remain_VB
have_VB [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
the_DT
basis_NN
of_PIN
IFRSs_NN
endorsed_VBN [WZPAST]
by_PIN
the_DT
EU_NN
._.
expected_VBN [PRIV]
to_TO
be_VB [BEMA]
available_PRED
at_PIN
31_CD
December_NN
2005_CD
._.
These_DEMP
are_VPRT [BEMA]
subject_PRED
to_PIN
ongoing_JJ
review_NN
AstraZenecas_NN
management_NOMZ
considers_VPRT [PRIV]
the_DT
Employee_NN
benefits_NN
and_PHC
endorsement_NOMZ
by_PIN
the_DT
EU_NN
or_CC
possible_JJ
following_VBG
to_TO
be_VB [BEMA]
the_DT
most_EMPH
important_JJ
The_DT
Group_NN
accounts_NN
for_PIN
pensions_NN
and_CC
similar_JJ
amendment_NOMZ
by_PIN
interpretative_JJ
guidance_NN
from_PIN
accounting_VBG
policies_NN
in_PIN
the_DT
context_NN
of_PIN
the_DT
benefits_NN
principally_RB
healthcare_NN
under_IN
IAS_NN
19_CD
the_DT
IASB_NN
International_NN
Accounting_GER
Groups_NN
operations_NOMZ
._.
In_PIN
respect_NN
of_PIN
defined_VBN
Standards_NN
Board_NN
and_CC
are_VPRT [SPAU]
therefore_CONJ
still_RB
benefit_VB
plans_NN
,_,
obligations_NOMZ
are_VPRT [PASS]
measured_VBN
at_PIN
subject_JJ
to_TO
change_VB
._.
We_FPP1
will_PRMD
update_VB
our_FPP1
Revenue_NN
discounted_VBD
present_JJ
value_NN
whilst_OSUB
plan_NN
assets_NN
restated_VBN
information_NOMZ
as_RB
necessary_JJ
for_PIN
any_QUAN
Turnover_NN
excludes_VPRT
inter-company_JJ
sales_NN
and_CC
are_VPRT [PASS]
recorded_VBN
at_PIN
fair_JJ
value_NN
._.
The_DT
operating_GER
and_CC
such_JJ
changes_NN
,_,
should_NEMD
they_TPP3
occur_VPRT
._.
value-added_JJ
taxes_NN
and_CC
represents_VPRT
net_JJ
financing_GER
costs_NN
of_PIN
such_JJ
plans_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
invoice_JJ
value_NN
less_RB
estimated_JJ
rebates_NN
,_,
returns_NN
separately_RB
in_PIN
the_DT
income_NN
statement_NOMZ
:_:
service_NN
Basis_NN
of_PIN
preparation_NOMZ
and_PHC
settlement_NOMZ
discounts_NN
._.
Turnover_NN
is_VPRT
costs_NN
are_VPRT [PASS]
spread_VBN
systematically_RB
over_IN
the_DT
lives_NN
The_DT
financial_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [BEMA]
prepared_PRED
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
significant_JJ
risks_NN
and_CC
of_PIN
employees_NN
and_PHC
financing_GER
costs_NN
are_VPRT [BEMA]
in_PIN
accordance_NN
with_PIN
IFRS_NN
as_IN
adopted_VBN
by_PIN
the_DT
rewards_NN
of_PIN
ownership_NN
have_VPRT [PEAS]
been_VBN [PASS]
transferred_VBN
recognized_VBN [PRIV]
in_PIN
the_DT
periods_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
The_DT
accounting_GER
policies_NN
applied_VBN [WZPAST]
are_VPRT [PASS]
set_VBN
to_PIN
a_DT
third_JJ
party_NN
._.
Actuarial_JJ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
out_PIN
on_PIN
pages_NN
139_CD
to_PIN
141_CD
._.
immediately_TIME
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
Research_NN
and_PHC
development_NOMZ
income_NN
and_PHC
expense_NN
._.
All_QUAN
IASB_NN
standards_NN
in_PIN
issue_NN
at_PIN
December_NN
Research_NN
expenditure_NN
is_VPRT [PASS]
charged_VBN
to_PIN
income_NN
2004_CD
have_VPRT [PEAS]
been_VBN [BYPA]
endorsed_VBN
by_PIN
the_DT
EU_NN
,_,
except_PIN
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
._.
Payments_NOMZ
to_TO
defined_VBN
contribution_NOMZ
schemes_NN
as_IN
noted_VBN [PRIV]
below_PLACE
:_:
are_VPRT [PASS]
charged_VBN
as_IN
an_DT
expense_NN
as_IN
they_TPP3
fall_VPRT
due_JJ
._.
Internal_NN
development_NOMZ
expenditure_NN
is_VPRT [PASS]
charged_VBN
The_DT
EU_NN
has_VPRT [PEAS]
issued_VBN
a_DT
revised_VBN
version_NN
of_PIN
to_PIN
income_NN
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [PASS]
incurred_VBN
Share-based_JJ
payments_NOMZ
IAS_NN
39_CD
referred_VBD
to_PIN
as_IN
the_DT
carve_VPRT
out_PIN
unless_COND
it_PIT
meets_VPRT
the_DT
recognition_NOMZ
criteria_NN
of_PIN
IAS_NN
The_NN
fair_JJ
value_NN
of_PIN
employee_NN
share_NN
option_NOMZ
plans_VPRT
version_NN
and_CC
has_VPRT [PEAS]
endorsed_VBN
this_DEMO
rather_RB
38_CD
Intangible_NN
Assets_NN
._.
Regulatory_NN
and_CC
other_JJ
is_VPRT [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
Black-Scholes_NN
model_NN
._.
than_PIN
the_DT
full_JJ
IASB_NN
standard_NN
._.
uncertainties_NN
generally_RB
mean_VPRT [PRIV]
that_THVC
such_JJ
In_PIN
accordance_NN
with_PIN
IFRS_NN
2_CD
Share-based_JJ
The_DT
IASB_NN
has_VPRT [PEAS]
issued_VBN
amendments_NOMZ
to_PIN
criteria_NN
are_VPRT [PASS]
not_XX0
met_VBN
._.
Where_RB
,_,
however_CONJ
,_,
the_DT
Payments_NOMZ
the_DT
resulting_VBG
cost_NN
is_VPRT [PASS]
charged_VBN
to_PIN
IAS_NN
19_CD
allowing_VBG [SUAV]
actuarial_JJ
gains_NN
or_CC
losses_NN
recognition_NOMZ
criteria_NN
are_VPRT [PASS]
met_VBN
,_,
intangible_JJ
assets_NN
the_DT
income_NN
statement_NOMZ
over_IN
the_DT
vesting_JJ
period_NN
are_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
their_TPP3
of_PIN
the_DT
options_NOMZ
._.
The_DT
value_NN
of_PIN
the_DT
charge_NN
is_VPRT
References_NN
to_PIN
IFRS_NN
refer_VPRT
to_PIN
the_DT
application_NOMZ
of_PIN
useful_JJ
economic_JJ
lives_NN
from_PIN
product_NN
launch_NN
._.
adjusted_VBN
to_TO
reflect_VB [PRIV]
expected_VBN [PRIV]
and_CC
actual_JJ
levels_NN
International_NN
Accounting_GER
Standards_NN
,_,
Payments_NOMZ
to_PIN
in-license_JJ
products_NN
and_CC
of_PIN
options_NOMZ
vesting_GER
._.
International_NN
Financial_NN
Reporting_GER
Standards_NN
compounds_VPRT
from_PIN
external_JJ
third_JJ
parties_NN
,_,
and_ANDC
Standing_VBG
Interpretations_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
International_NN
Financial_NN
Reporting_GER
generally_RB
taking_VBG
the_DT
form_NN
of_PIN
up-front_JJ
Interpretations_NOMZ
Committee_NN
IFRIC_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
140_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
IFRS_NN
Restatements_NOMZ
continued_VBD
Foreign_JJ
currencies_NN
Tangible_JJ
fixed_VBN
assets_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
income_NN
statement_NOMZ
Profit_NN
and_PHC
loss_NN
accounts_NN
in_PIN
foreign_JJ
currencies_NN
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
write_VB [PUBV]
off_PIN
the_DT
on_PIN
the_DT
equity_NOMZ
accounting_GER
basis_NN
._.
The_DT
holding_GER
are_VPRT [PASS]
translated_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
average_JJ
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
each_QUAN
tangible_JJ
value_NN
of_PIN
significant_JJ
associates_NN
and_CC
joint_JJ
exchange_NN
rates_NN
for_PIN
the_DT
relevant_JJ
accounting_GER
fixed_VBN
asset_NN
and_CC
its_PIT
residual_JJ
value_NN
ventures_NN
in_PIN
the_DT
Group_NN
balance_NN
sheet_NN
is_VPRT
periods_NN
._.
Assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
translated_VBN
systematically_RB
over_IN
its_PIT
estimated_VBN [PRIV]
useful_JJ
life_NN
._.
calculated_VBN [PRIV] [PASTP]
by_PIN
reference_NN
to_PIN
AstraZenecas_NN
at_PIN
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
of_PIN
the_DT
Reviews_NN
are_VPRT [PASS]
made_VBN
annually_RB
of_PIN
the_DT
estimated_VBN [PRIV]
equity_NOMZ
in_PIN
the_DT
net_JJ
assets_NN
of_PIN
such_JJ
associates_NN
Group_NN
balance_NN
sheet_NN
._.
remaining_VBG
lives_NN
and_CC
residual_JJ
values_NN
of_PIN
and_CC
joint_JJ
ventures_NN
,_,
as_IN
shown_VBN [PRIV]
by_PIN
the_DT
most_EMPH
individual_JJ
productive_JJ
assets_NN
,_,
taking_VBG
account_NN
recent_JJ
accounts_NN
available_JJ
,_,
adjusted_VBN
where_RB
Exchange_NN
gains_NN
and_PHC
losses_NN
on_PIN
short_JJ
term_NN
of_PIN
commercial_JJ
and_PHC
technological_JJ
appropriate_JJ
and_CC
including_VBG
goodwill_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
and_PHC
deposits_NN
obsolescence_NN
as_RB
well_RB
as_IN
normal_JJ
wear_NN
and_PHC
acquisitions_NOMZ
made_VBD
since_OSUB
1_CD
January_NN
1998_CD
._.
are_VPRT [PASS]
included_VBN
within_PIN
net_JJ
interest_NN
payable_JJ
._.
Under_IN
this_DEMO
policy_NN
it_PIT
becomes_VPRT
impractical_JJ
Exchange_NN
differences_NN
on_PIN
all_QUAN
other_JJ
to_TO
calculate_VB [PRIV] [THATD]
average_JJ
assets_NN
lives_VPRT
exactly_RB
._.
Contingent_JJ
liabilities_NOMZ
transactions_NOMZ
,_,
except_PIN
relevant_JJ
foreign_JJ
However_CONJ
,_,
the_DT
total_JJ
lives_NN
range_VPRT
from_PIN
Through_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
,_,
currency_NN
loans_NN
,_,
are_VPRT [PASS]
taken_VBN
to_TO
operating_VBG
profit_NN
._.
approximately_RB
13_CD
to_PIN
50_CD
years_NN
for_PIN
buildings_GER
,_,
AstraZeneca_NN
is_VPRT [PASS]
involved_VBN
in_PIN
legal_JJ
disputes_NN
,_,
the_DT
In_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
,_,
and_ANDC
three_CD
to_PIN
15_CD
years_NN
for_PIN
plant_NN
and_PHC
settlement_NOMZ
of_PIN
which_WDT [PIRE]
may_POMD
involve_VB
cost_NN
to_PIN
the_DT
exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
equipment_NOMZ
._.
All_QUAN
tangible_JJ
fixed_JJ
assets_NN
are_VPRT
Group_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
where_RB
an_DT
adverse_JJ
consolidation_NOMZ
of_PIN
the_DT
net_JJ
investments_NOMZ
in_PIN
reviewed_VBN
for_PIN
impairment_NOMZ
when_RB
there_EX
are_VPRT
outcome_NN
is_VPRT [BEMA]
probable_PRED
and_CC
associated_VBN
costs_NN
subsidiaries_NN
,_,
joint_JJ
ventures_NN
and_PHC
associates_NN
,_,
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB
can_POMD
be_VB [PASS]
estimated_VBN [PRIV]
reliably_RB
._.
together_RB
with_PIN
those_DEMO
on_PIN
relevant_JJ
foreign_JJ
recoverable_JJ
._.
currency_NN
loans_NN
,_,
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
AstraZeneca_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
environmental_JJ
via_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_CC
Leases_VPRT
liabilities_NOMZ
relating_VBG [WZPRES]
to_PIN
its_PIT
past_JJ
operations_NOMZ
,_,
expense_NN
._.
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT [BEMA]
principally_RB
in_PIN
respect_NN
of_PIN
soil_NN
and_PHC
groundwater_NN
capitalized_VBN
and_PHC
included_VBN
in_PIN
tangible_JJ
fixed_VBN
remediation_NOMZ
costs_NN
._.
Provisions_NN
for_PIN
these_DEMO
costs_NN
Taxation_NOMZ
assets_NN
at_PIN
fair_JJ
value_NN
._.
Each_QUAN
asset_NN
is_VPRT [PASS]
depreciated_VBN
are_VPRT [PASS]
made_VBN
when_RB
there_EX
is_VPRT
a_DT
present_JJ
obligation_NOMZ
The_DT
charge_NN
for_PIN
taxation_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
lease_NN
term_NN
or_CC
its_PIT
useful_JJ
and_ANDC
where_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
expenditure_NN
on_PIN
profits_NN
for_PIN
the_DT
year_NN
and_CC
takes_VPRT
into_PIN
account_NN
life_NN
._.
The_DT
obligations_NOMZ
related_VBN
to_TO
finance_VB
leases_NN
,_,
remedial_JJ
work_NN
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
and_CC
that_THVC
a_DT
taxation_NOMZ
deferred_VBN
because_CAUS
of_PIN
temporary_JJ
net_NN
of_PIN
finance_NN
charges_NN
in_PIN
respect_NN
of_PIN
future_JJ
reliable_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
cost_NN
._.
differences_NN
between_PIN
the_DT
treatment_NOMZ
of_PIN
certain_JJ
periods_NN
,_,
are_VPRT [PASS]
included_VBN
,_,
as_IN
appropriate_JJ
,_,
under_IN
items_NN
for_PIN
taxation_NOMZ
and_CC
for_PIN
accounting_GER
creditors_NN
due_JJ
within_PIN [STPR]
,_,
or_CC
creditors_NN
due_RB
after_IN
Inventories_NN
purposes_NN
._.
Full_JJ
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
the_DT
tax_NN
more_EMPH
than_PIN [STPR]
,_,
one_CD
year_NN
._.
The_DT
interest_NN
element_NOMZ
of_PIN
Inventories_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
or_CC
effects_NN
of_PIN
these_DEMO
differences_NN
._.
Deferred_JJ
tax_NN
the_DT
rental_JJ
obligation_NOMZ
is_VPRT [PASS]
allocated_VBN
to_PIN
net_JJ
realisable_JJ
value_NN
._.
The_DT
first_JJ
in_PIN [STPR]
,_,
first_RB
out_PIN
or_CC
an_DT
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT
accounting_VBG
periods_NN
during_PIN
the_DT
lease_NN
term_NN
to_PIN
average_JJ
method_NN
of_PIN
valuation_NOMZ
is_VPRT [PASS]
used_VBN
._.
For_PIN
probable_JJ
that_THAC
taxable_JJ
profit_NN
will_PRMD
be_VB [BEMA]
available_PRED
reflect_VPRT [PRIV]
a_DT
constant_JJ
rate_NN
of_PIN
interest_NN
on_PIN
the_DT
finished_VBN
goods_NN
and_PHC
work_NN
in_PIN
progress_NN
,_,
cost_NN
against_PIN
which_WDT [PIRE]
the_DT
asset_NN
can_POMD
be_VB [PASS]
utilised_VBN
._.
This_DEMP
remaining_VBG
balance_NN
of_PIN
the_DT
obligation_NOMZ
for_PIN
each_QUAN
includes_VPRT
directly_RB
attributable_JJ
costs_NN
and_CC
requires_VPRT [SUAV]
judgements_NOMZ
to_TO
be_VB [PASS]
made_VBN
in_PIN
respect_NN
of_PIN
accounting_GER
period_NN
._.
certain_JJ
overhead_NN
expenses_NN
including_VBG [WZPRES]
the_DT
forecast_NN
of_PIN
future_JJ
taxable_JJ
income_NN
._.
Selling_VBG
expenses_NN
and_CC
certain_JJ
Rentals_NN
under_IN
operating_VBG
leases_NN
are_VPRT [PASS]
charged_VBN
other_JJ
overhead_NN
expenses_NN
principally_RB
central_JJ
No_DT
deferred_VBN
tax_NN
asset_NN
or_CC
liability_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
income_NN
statement_NOMZ
as_IN
incurred_VBN
._.
Net_NN
in_PIN
respect_NN
of_PIN
temporary_JJ
differences_NN
realisable_JJ
value_NN
is_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
as_IN
estimated_VBN [PRIV]
associated_VBN
with_PIN
investments_NOMZ
in_PIN
subsidiaries_NN
,_,
Subsidiaries_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
selling_VBG [WZPRES]
price_NN
less_RB
all_QUAN
estimated_VBN [PRIV]
costs_NN
of_PIN
branches_NN
,_,
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
A_DT
subsidiary_NN
is_VPRT [BEMA]
an_DT
entity_NOMZ
controlled_VBN
,_,
directly_RB
or_CC
completion_NOMZ
and_PHC
costs_NN
to_TO
be_VB [PASS]
incurred_VBN
in_PIN
where_RB
the_DT
Group_NN
is_VPRT [BEMA]
able_PRED
to_TO
control_VB
the_DT
timing_NN
indirectly_RB
,_,
by_PIN
AstraZeneca_NN
PLC._NN
._.
Control_NN
is_VPRT
marketing_GER
,_,
selling_VBG
and_CC
distribution_NOMZ
._.
of_PIN
reversal_NN
of_PIN
the_DT
temporary_JJ
differences_NN
and_CC
it_PIT
regarded_VBD
as_IN
the_DT
power_NN
to_TO
govern_VB
the_DT
financial_JJ
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
temporary_JJ
differences_NN
will_PRMD
and_CC
operating_VBG
policies_NN
of_PIN
the_DT
entity_NOMZ
so_RB
as_IN
to_PIN
Financial_NN
instruments_NOMZ
not_XX0
reverse_VB
in_PIN
the_DT
foreseeable_JJ
future_NN
._.
obtain_VB
benefits_NN
from_PIN
its_PIT
activities_NOMZ
._.
Financial_NN
instruments_NOMZ
are_VPRT [PASS]
recorded_VBN
initially_TIME
at_PIN
fair_JJ
value_NN
._.
Subsequent_JJ
measurement_NOMZ
Accruals_NN
for_PIN
tax_NN
contingencies_NN
require_VPRT [SUAV] [THATD]
An_DT
associate_NN
is_VPRT [BEMA]
an_DT
undertaking_GER
,_,
not_XX0
being_VBG [BEMA]
a_DT
depends_VPRT
on_PIN
the_DT
designation_NOMZ
of_PIN
the_DT
management_NOMZ
to_TO
make_VB
judgements_NOMZ
and_PHC
subsidiary_NN
or_CC
joint_JJ
venture_NN
,_,
in_PIN
which_WDT [PIRE]
instrument_NOMZ
,_,
as_IN
follows_VPRT
:_:
estimates_NN
of_PIN
ultimate_JJ
exposures_NN
in_PIN
relation_NOMZ
to_PIN
AstraZeneca_NN
has_VPRT
a_DT
participating_VBG
interest_NN
and_PHC
tax_NN
audit_NN
issues_NN
and_PHC
exposures_NN
._.
Tax_NN
benefits_NN
over_IN
whose_WPS
commercial_JJ
and_PHC
financial_JJ
policy_NN
Investments_NOMZ
other_JJ
than_PIN
interests_NN
in_PIN
joint_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
unless_COND
the_DT
tax_NN
positions_NOMZ
decisions_NN
AstraZeneca_NN
has_VPRT
the_DT
power_NN
to_PIN
ventures_NN
,_,
associates_NN
and_CC
fixed_VBN
deposits_NN
will_PRMD [SPAU]
probably_RB
be_VB [PASS]
sustained_VBN
._.
Once_TIME
considered_VBN [PRIV]
exert_NN
significant_JJ
influence_NN
._.
and_ANDC
short_JJ
term_NN
investments_NOMZ
other_JJ
than_PIN
to_TO
be_VB [BEMA]
probable_PRED
,_,
management_NOMZ
reviews_NN
each_QUAN
fixed_VBN
deposits_NN
are_VPRT [SPAU] [PASS]
normally_RB
designated_VBN
material_NN
tax_NN
benefit_NN
to_TO
assess_VB
whether_IN
a_DT
A_DT
joint_JJ
venture_NN
is_VPRT [BEMA]
an_DT
entity_NOMZ
in_PIN
which_WDT [PIRE]
as_IN
available_JJ
for_PIN
sale_NN
._.
Where_RB
the_DT
exposure_NN
provision_NN
should_NEMD
be_VB [PASS]
taken_VBN
against_PIN
full_JJ
AstraZeneca_NN
holds_VPRT [PRIV]
an_DT
interest_NN
on_PIN
a_DT
long_JJ
term_NN
to_PIN
a_DT
change_NN
in_PIN
fair_JJ
value_NN
of_PIN
such_PDT
an_DT
asset_NN
recognition_NOMZ
of_PIN
that_DEMO
benefit_NN
on_PIN
the_DT
basis_NN
of_PIN
a_DT
basis_NN
and_ANDC
which_WDT
is_VPRT [SPAU] [BYPA]
jointly_RB
controlled_VBN
by_PIN
is_VPRT [SPAU] [BYPA]
substantially_RB
offset_VBN
by_PIN
the_DT
exposure_NN
to_PIN
potential_JJ
settlement_NOMZ
through_PIN
negotiation_NOMZ
AstraZeneca_NN
and_CC
one_CD
or_CC
more_EMPH
other_JJ
a_DT
change_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
derivatives_NN
,_,
and_ANDC
or_CC
litigation_NOMZ
._.
Any_QUAN
recorded_VBN
exposure_NN
to_PIN
venturers_NN
under_IN
a_DT
contractual_JJ
arrangement_NOMZ
._.
the_DT
asset_NN
is_VPRT [SPAU] [PASS]
generally_RB
classified_VBN
as_IN
fair_JJ
the_DT
interest_NN
on_PIN
tax_NN
liabilities_NOMZ
is_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
value_NN
through_PIN
profit_NN
or_CC
loss_NN
._.
AstraZenecas_NN
share_NN
of_PIN
the_DT
profit_NN
less_RB
losses_NN
of_PIN
all_QUAN
significant_JJ
joint_JJ
ventures_NN
and_PHC
associates_NN
Fixed_VBN
deposits_NN
,_,
comprising_VBG [PRESP]
principally_RB
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
141_CD
funds_NN
held_VBN [PRIV] [WZPAST]
with_PIN
banks_NN
and_CC
other_JJ
financial_JJ
In_CONJ
addition_NULL
the_DT
Group_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
restate_VB
institutions_NOMZ
,_,
and_ANDC
short_JJ
term_NN
borrowings_GER
comparative_JJ
information_NOMZ
with_PIN
respect_NN
to_TO
and_CC
overdrafts_NN
are_VPRT [PASS]
classified_VBN
as_IN
loans_NN
and_PHC
IAS_NN
32_CD
,_,
IAS_NN
39_CD
and_CC
IFRS_NN
2_CD
._.
receivables_NN
and_CC
held_VBN [PRIV]
at_PIN
amortised_JJ
cost_NN
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
opted_VBN
to_TO
adopt_VB
the_DT
IASB_NN
Derivatives_NN
,_,
comprising_VBG
interest_NN
rate_NN
amendments_NOMZ
to_PIN
IAS_NN
19_CD
early_TIME
,_,
allowing_VBG [SUAV]
swaps_NN
,_,
foreign_JJ
exchange_NN
contracts_NN
and_CC
actuarial_JJ
gains_NN
and_PHC
losses_NN
to_TO
be_VB [PASS]
charged_VBN
to_PIN
options_NOMZ
and_CC
embedded_VBN
derivatives_NN
,_,
are_VPRT
reserves_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
classified_VBN
as_IN
held_VBN [PRIV]
for_PIN
trading_GER
._.
Changes_NN
in_PIN
fair_JJ
value_NN
are_VPRT [PASS]
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
Long_JJ
term_NN
loans_NN
are_VPRT [SPAU] [PASS]
generally_RB
held_VBN [PRIV]
at_PIN
amortised_JJ
cost_NN
._.
Where_RB
a_DT
derivative_JJ
financial_JJ
instrument_NOMZ
generally_RB
an_DT
interest_NN
rate_NN
swap_NN
hedges_NN
the_DT
changes_NN
in_PIN
fair_JJ
value_NN
of_PIN
a_DT
long_JJ
term_NN
loan_NN
,_,
any_QUAN
gain_NN
or_CC
loss_NN
on_PIN
the_DT
hedging_VBG
instrument_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
The_DT
hedged_VBN
item_NN
is_VPRT [SPAU] [PASS]
also_RB
stated_VBN [PUBV]
at_PIN
fair_JJ
value_NN
in_PIN
respect_NN
of_PIN
the_DT
risk_NN
being_VBG [WZPRES] [PASS]
hedged_VBN
,_,
with_PIN
any_QUAN
gain_NN
or_CC
loss_NN
being_VBG [WZPRES] [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Changes_NN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
dealt_VBN
with_PIN
as_IN
follows_VPRT
:_:
For_PIN
available_JJ
for_PIN
sale_NN
assets_NN
,_,
exchange_NN
losses_NN
and_PHC
impairments_NOMZ
are_VPRT [PASS]
taken_VBN
to_PIN
the_DT
income_NN
statement_NOMZ
._.
All_QUAN
other_JJ
changes_NN
in_PIN
fair_JJ
value_NN
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
._.
On_PIN
disposal_NN
of_PIN
the_DT
related_JJ
asset_NN
,_,
the_DT
accumulated_VBN
changes_NN
in_PIN
fair_JJ
value_NN
recorded_VBN [WZPAST]
in_PIN
reserves_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
gain_NN
or_CC
loss_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
For_PIN
long_JJ
term_NN
loans_NN
effectively_RB
hedged_VBN
,_,
assets_NN
at_PIN
fair_JJ
value_NN
through_PIN
profit_NN
or_CC
loss_NN
and_PHC
assets_NN
held_VBN [PRIV] [WZPAST]
for_PIN
trading_GER
,_,
all_QUAN
changes_NN
in_PIN
fair_JJ
value_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
IFRS_NN
transitional_JJ
arrangements_NOMZ
and_CC
early_TIME
adoption_NOMZ
When_RB
preparing_VBG
the_DT
Groups_NN
IFRS_VPRT
balance_NN
sheet_NN
at_PIN
1_CD
January_NN
2003_CD
,_,
the_DT
date_NN
of_PIN
transition_NOMZ
,_,
the_DT
following_VBG
optional_JJ
exemptions_NOMZ
from_PIN
full_JJ
retrospective_JJ
application_NOMZ
of_PIN
IFRS_NN
accounting_GER
policies_NN
have_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
:_:
Business_NOMZ
combinations_NOMZ
the_DT
provisions_NN
of_PIN
IFRS_NN
3_CD
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
prospectively_RB
from_PIN
1_CD
January_NN
2003_CD
:_:
and_ANDC
Employee_NN
benefits_VPRT
the_DT
accumulated_VBN
actuarial_JJ
gains_NN
and_PHC
losses_NN
in_PIN
respect_NN
of_PIN
employee_NN
defined_VBN
benefit_NN
plans_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
through_PIN
reserves_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
142_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
IFRS_NN
Restatements_NOMZ
continued_VBD
Reconciliation_NOMZ
of_PIN
profit_NN
IFRS_NN
2_CD
IAS_NN
32_CD
Reported_VBN [PUBV]
ShareIAS_NN
19_CD
IAS_NN
39_CD
Restated_VBN
under_IN
UK_NN
based_VBN
Employee_NN
Financial_NN
under_IN
GAAP_NN
Payments_NOMZ
Benefits_NN
Instruments_NOMZ
Other_JJ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Sales_NN
21,42621,426_CD
Cost_NN
of_PIN
sales_NN
5,150_CD
2_CD
41_CD
5,193_CD
Distribution_NOMZ
costs_VPRT
177_CD
177_CD
Research_NN
and_PHC
development_NOMZ
3,803_CD
42_CD
1_CD
24_CD
403_CD
3,467_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
7,841_CD
103_CD
10_CD
334_CD
8,268_CD
Other_JJ
operating_GER
income_NN
315_CD
89_CD
226_CD
Operating_GER
profit_NN
4,770_CD
147_CD
9_CD
154_CD
69_CD
4,547_CD
Net_NN
finance_NN
costs_NN
90_CD
8_CD
28_CD
1_CD
53_CD
Income_NN
from_PIN
dividends_NN
6_CD
6_CD
Profit_NN
on_PIN
sale_NN
of_PIN
interest_NN
in_PIN
joint_JJ
venture_NN
219_CD
219_CD
Profit_NN
before_IN
tax_NN
5,085_CD
147_CD
1_CD
182_CD
68_CD
4,825_CD
Taxation_NOMZ
1,254_CD
20_CD
1_CD
54_CD
66_CD
1,155_CD
Profit_NN
for_PIN
the_DT
period_NN
3,831_CD
167 128 134_CD
3,670_CD
Attributable_JJ
to_TO
:_:
Equity_NOMZ
holders_NN
of_PIN
the_DT
Company_NN
3,813_CD
167_CD
1_CD
128_CD
134_CD
3,651_CD
Minority_NOMZ
interest_NN
18_CD
1_CD
19_CD
Basic_JJ
earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
$_$
2.28_CD
$_$
0.10_CD
$_$
0.00_CD
$_$
0.08_CD
$_$
0.08_CD
$_$
2.18_CD
Diluted_VBN
earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
$_$
2.28_CD
$_$
0.10_CD
$_$
0.00_CD
$_$
0.08_CD
$_$
0.08_CD
$_$
2.18_CD
Statement_NOMZ
of_PIN
Recognised_NN
Income_NN
and_PHC
Expense_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
$_$
m_CD [BEMA]
Net_JJ
profit_NN
for_PIN
the_DT
period_NN
3,651_CD
Foreign_NN
exchange_NN
adjustments_NOMZ
on_PIN
consolidation_NOMZ
689_CD
Tax_NN
on_PIN
foreign_JJ
exchange_NN
adjustments_NOMZ
379_CD
Valuation_NOMZ
gains_NN
taken_VBN [WZPAST]
to_PIN
equity_NOMZ
39_CD
Actuarial_NN
gains_NN
and_PHC
losses_NN
,_,
net_NN
of_PIN
tax_NN
98_CD
Recognised_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
year_NN
4,660_CD
Tax_NN
on_PIN
foreign_JJ
exchange_NN
adjustments_NOMZ
on_PIN
consolidation_NOMZ
in_PIN
2004_CD
includes_VPRT
a_DT
credit_NN
of_PIN
$_$
357m_CD
in_PIN
respect_NN
of_PIN
foreign_JJ
exchange_NN
losses_NN
arising_VBG [WZPRES]
in_PIN
2000_CD
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
143_CD
Reconciliation_NOMZ
of_PIN
profit_NN
IFRS_NN
2_CD
IAS_NN
32_CD
Reported_VBN [PUBV]
ShareIAS_NN
19_CD
IAS_NN
39_CD
Restated_VBN
under_IN
UK_NN
based_VBN
Employee_NN
Financial_NN
under_IN
GAAP_NN
Payments_NOMZ
Benefits_NN
Instruments_NOMZ
Other_JJ
IFRS_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Sales_NN
18,849_CD
18,849_CD
Cost_NN
of_PIN
sales_NN
4,469_CD
2_CD
2_CD
11_CD
1_CD
4,463_CD
Distribution_NOMZ
costs_NN
162_CD
162_CD
Research_NN
and_PHC
development_NOMZ
3,451_CD
42_CD
5_CD
486_CD
3,012_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
6,856_CD
110_CD
7_CD
4_CD
424_CD
7,393_CD
Other_JJ
operating_GER
income_NN
200_CD
12_CD
188_CD
Operating_GER
profit_NN
4,111_CD
154_CD
14_CD
3_CD
61_CD
4,007_CD
Net_NN
finance_NN
costs_NN
89_CD
7_CD
24_CD
2_CD
56_CD
Income_NN
from_PIN
dividends_NN
2_CD
2_CD
Profit_NN
before_IN
tax_NN
4,202_CD
154_CD
21_CD
21_CD
59_CD
4,065_CD
Taxation_NOMZ
1,143_CD
18_CD
6_CD
5_CD
85_CD
1,029_CD
Profit_NN
for_PIN
the_DT
year_NN
3,059_CD
136_CD
15_CD
16_CD
144_CD
3,036_CD
Attributable_JJ
to_TO
:_:
Equity_NOMZ
holders_NN
of_PIN
the_DT
Company_NN
3,036_CD
136_CD
14_CD
16_CD
144_CD
3,014_CD
Minority_NOMZ
interest_NN
23_CD
1_CD
22_CD
Basic_JJ
earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
$_$
1.78_CD
$_$
0.08_CD
$_$
0.01_CD
$_$
0.01_CD
$_$
0.08_CD
$_$
1.76_CD
Diluted_VBN
earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
$_$
1.78_CD
$_$
0.08_CD
$_$
0.01_CD
$_$
0.01_CD
$_$
0.08_CD
$_$
1.76_CD
Statement_NOMZ
of_PIN
Recognised_NN
Gains_NN
and_PHC
Losses_NN
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
$_$
m_CD [BEMA]
Net_JJ
profit_NN
for_PIN
the_DT
period_NN
3,014_CD
Foreign_NN
exchange_NN
adjustments_NOMZ
on_PIN
consolidation_NOMZ
1,256_CD
Tax_NN
on_PIN
foreign_JJ
exchange_NN
adjustments_NOMZ
66_CD
Valuation_NOMZ
gains_NN
taken_VBN [WZPAST]
to_PIN
equity_NOMZ
10_CD
Actuarial_JJ
gains_NN
and_PHC
losses_NN
,_,
net_NN
of_PIN
tax_NN
167_CD
Recognised_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
year_NN
4,179_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
144_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
IFRS_NN
Restatements_NOMZ
continued_VBD
Reconciliation_NOMZ
of_PIN
equity_NOMZ
IAS_NN
32_CD
Reported_VBN [PUBV]
IAS_NN
19_CD
IAS_NN
39_CD
IAS_NN
12_CD
under_IN
UK_NN
Employee_NN
Financial_NN
Income_NN
Restated_NN
GAAP_NN
Benefits_NN
Instruments_NOMZ
Tax_NN
Other_JJ
under_IN
IFRS_NN
As_IN
at_PIN
31_CD
December_NN
2004_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Assets_NN
Non-current_JJ
assets_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
8,083_CD
14_CD
8,097_CD
Goodwill_NN
and_CC
intangible_JJ
assets_NN
2,826_CD
224_CD
3,050_CD
Other_JJ
investments_NOMZ
267_CD
5_CD
262_CD
Deferred_JJ
tax_NN
assets_NN
548_CD
31_CD
1,016_CD
1_CD
1,594_CD
11,176_CD
548_CD
26_CD
1,016_CD
237_CD
13,003_CD
Current_JJ
assets_NN
Inventories_NN
3,020_CD
3,020_CD
Trade_NN
and_CC
other_JJ
receivables_NN
6,274_CD
720_CD
781_CD
2_CD
4,771_CD
Short_JJ
term_NN
investments_NOMZ
,_,
cash_NN
and_PHC
cash_NN
equivalents_NN
5,146_CD
88_CD
5,234_CD
14,440_CD
720_CD
88_CD
781_CD
2_CD
13,025_CD
Total_JJ
assets_NN
25,616_CD
172 114 235 235_CD
26,028_CD
Liabilities_NOMZ
Current_JJ
liabilities_NOMZ
Short_JJ
term_NN
borrowings_GER
,_,
overdrafts_NN
and_CC
current_JJ
instalments_NOMZ
of_PIN
loans_NN
142_CD
142_CD
Other_JJ
creditors_NN
7,640_CD
111_CD
25_CD
1,059_CD
6,445_CD
7,782_CD
111_CD
25_CD
1,059_CD
6,587_CD
Non-current_JJ
liabilities_NOMZ
Loans_NN
1,030_CD
68_CD
1,098_CD
Retirement_NOMZ
benefit_NN
obligations_NOMZ
1,761_CD
1,761_CD
Provisions_NN
and_CC
deferred_VBN
tax_NN
liabilities_NOMZ
2,207_CD
387_CD
43_CD
107_CD
8_CD
1,978_CD
Other_JJ
liabilities_NOMZ
78_CD
8_CD
86_CD
3,315_CD
1,374_CD
111_CD
107_CD
16_CD
4,923_CD
Total_JJ
liabilities_NOMZ
11,097_CD
1,263_CD
86_CD
107_CD
1,043_CD
11,510_CD
Net_JJ
assets_NN
14,519_CD
1,435_CD
28_CD
128_CD
1,278_CD
14,518_CD
Equity_NOMZ
Capital_NN
and_PHC
reserves_NN
attributable_JJ
to_PIN
equity_NOMZ
holders_NN
Share_NN
capital_NN
411_CD
411_CD
Share_NN
premium_NN
account_NN
550_CD
550_CD
Other_JJ
reserves_NN
1,851_CD
1,851_CD
Retained_VBN
earnings_GER
11,606_CD
1,417_CD
28_CD
118_CD
1,278_CD
11,613_CD
14,418_CD
1,417_CD
28_CD
118_CD
1,278_CD
14,425_CD
Minority_NOMZ
equity_NOMZ
interests_NN
101_CD
18_CD
10_CD
93_CD
Total_JJ
equity_NOMZ
and_PHC
reserves_NN
14,519_CD
1,435_CD
28_CD
128_CD
1,278_CD
14,518_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
145_CD
Reconciliation_NOMZ
of_PIN
equity_NOMZ
IAS_NN
32_CD
Reported_VBN [PUBV]
IAS_NN
19_CD
IAS_NN
39_CD
IAS_NN
12_CD
under_IN
UK_NN
Employee_NN
Financial_NN
Income_NN
Restated_NN
GAAP_NN
Benefits_NN
Instruments_NOMZ
Tax_NN
Other_JJ
under_IN
IFRS_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Assets_NN
Non-current_JJ
assets_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
7,536_CD
11_CD
7,547_CD
Goodwill_NN
and_CC
intangible_JJ
assets_NN
2,884_CD
143_CD
3,027_CD
Other_JJ
investments_NOMZ
220_CD
7_CD
80_CD
133_CD
Deferred_JJ
tax_NN
assets_NN
472_CD
2_CD
1,021_CD
19_CD
1,514_CD
10,640_CD
472_CD
5_CD
1,021_CD
93_CD
12,221_CD
Current_JJ
assets_NN
Inventories_NN
3,022_CD
3,022_CD
Trade_NN
and_CC
other_JJ
receivables_NN
5,960_CD
643_CD
897_CD
4,420_CD
Short_JJ
term_NN
investments_NOMZ
,_,
cash_NN
and_PHC
cash_NN
equivalents_NN
3,951_CD
200_CD
4,151_CD
12,933_CD
643 200 897_CD
11,593_CD
Total_JJ
assets_NN
23,573_CD
171 195 124_CD
93_CD
23,814_CD
Liabilities_NOMZ
Current_JJ
liabilities_NOMZ
Short_JJ
term_NN
borrowings_GER
,_,
overdrafts_NN
and_CC
current_JJ
instalments_NOMZ
of_PIN
loans_NN
152_CD
152_CD
Other_JJ
creditors_NN
7,543_CD
143_CD
994_CD
6,406_CD
7,695_CD
143_CD
994_CD
6,558_CD
Non-current_JJ
liabilities_NOMZ
Loans_NN
303_CD
303_CD
Retirement_NOMZ
benefit_NN
obligations_NOMZ
1,528_CD
1,528_CD
Provisions_NN
and_CC
deferred_VBN
tax_NN
liabilities_NOMZ
2,266_CD
314_CD
61_CD
132_CD
8_CD
2,153_CD
Other_JJ
liabilities_NOMZ
52_CD
11_CD
63_CD
2,621_CD
1,214_CD
61_CD
132_CD
19_CD
4,047_CD
Total_JJ
liabilities_NOMZ
10,316_CD
1,071_CD
61 132 975_CD
10,605_CD
Net_JJ
assets_NN
13,257_CD
1,242_CD
134_CD
8_CD
1,068_CD
13,209_CD
Equity_NOMZ
Capital_NN
and_PHC
reserves_NN
attributable_JJ
to_PIN
equity_NOMZ
holders_NN
Share_NN
capital_NN
423_CD
423_CD
Share_NN
premium_NN
account_NN
449_CD
449_CD
Other_JJ
reserves_NN
1,857_CD
1,857_CD
Retained_VBN
earnings_GER
10,449_CD
1,242_CD
134_CD
18_CD
1,068_CD
10,391_CD
13,178_CD
1,242_CD
134_CD
18_CD
1,068_CD
13,120_CD
Minority_NOMZ
equity_NOMZ
interests_NN
79_CD
10_CD
89_CD
Total_JJ
equity_NOMZ
and_PHC
reserves_NN
13,257_CD
1,242_CD
134_CD
8_CD
1,068_CD
13,209_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
IFRS_NN
Restatements_NOMZ
146_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
IFRS_NN
Restatements_NOMZ
continued_VBD
Consolidated_NN
Cash_NN
Flow_NN
Statement_NOMZ
2004_CD
2003_CD
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
Cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
Operating_VBG [WZPRES]
profit_NN
before_IN
taxation_NOMZ
4,547_CD
4,007_CD
Depreciation_NOMZ
,_,
amortisation_NOMZ
and_PHC
impairment_NOMZ
1,268_CD
1,293_CD
Increase_VPRT
in_PIN
working_VBG
capital_NN
9_CD
1,080_CD
Other_JJ
non-cash_JJ
movements_NOMZ
326_CD
73_CD
Cash_NN
from_PIN
operating_VBG
activities_NOMZ
6,132_CD
4,293_CD
Interest_NN
paid_VBN
69_CD
39_CD
Tax_NN
paid_VBD
1,246_CD
886_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
4,817_CD
3,368_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Disposal_NN
of_PIN
business_NOMZ
operations_NOMZ
355_CD
80_CD
Movement_NOMZ
in_PIN
short_JJ
term_NN
investments_NOMZ
and_CC
fixed_VBN
deposits_NN
1,855_CD
617_CD
Purchases_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
1,063_CD
1,282_CD
Disposals_NN
of_PIN
property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
35_CD
38_CD
Purchase_NN
of_PIN
intangible_JJ
assets_NN
215_CD
293_CD
Purchase_NN
of_PIN
fixed_JJ
asset_NN
investments_NOMZ
117_CD
120_CD
Interest_NN
received_VBD
119_CD
117_CD
Dividends_NN
paid_VBN [WZPAST]
by_PIN
subsidiaries_NN
to_PIN
minority_NOMZ
interests_NN
5_CD
11_CD
Dividends_NN
received_VBD
6_CD
2_CD
Net_JJ
cash_NN
inflow_NN
outflow_NN
from_PIN
investing_VBG
activities_NOMZ
970_CD
852_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Proceeds_NN
from_PIN
issue_NN
of_PIN
share_NN
capital_NN
102_CD
47_CD
Repurchase_NN
of_PIN
shares_NN
2,212_CD
1,154_CD
Increase_VPRT
in_PIN
repayment_NOMZ
of_PIN
loans_NN
725_CD
345_CD
Dividends_NN
paid_VBD
1,378_CD
1,222_CD
Increase_VPRT
in_PIN
short_JJ
term_NN
borrowings_GER
2_CD
Net_JJ
cash_NN
outflow_NN
from_PIN
financing_VBG
activities_NOMZ
2,761_CD
2,674_CD
Net_JJ
increase_NN
decrease_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
3,026_CD
158_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
the_DT
beginning_GER
of_PIN
the_DT
period_NN
872_CD
968_CD
Exchange_NN
movements_NOMZ
cash_NN
and_PHC
cash_NN
equivalents_NN
29_CD
62_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
period_NN
3,927_CD
872_CD
Cash_NN
and_PHC
cash_NN
equivalents_NN
consists_VPRT
of_PIN
:_:
Cash_NN
and_PHC
cash_NN
equivalents_NN
4,067_CD
1,024_CD
Overdrafts_NN
140_CD
152_CD
3,927_CD
872_CD
Reconciliation_NOMZ
of_PIN
Net_JJ
Cash_NN
and_PHC
Debt_NN
2004_CD
2003_CD
For_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
Increase_VPRT
decrease_NN
in_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
3,026_CD
158_CD
Cash_NN
inflow_NN
outflow_NN
from_PIN
increase_NN
decrease_NN
in_PIN
loans_NN
and_CC
short_JJ
term_NN
borrowings_GER
727_CD
345_CD
Cash_NN
inflow_NN
from_PIN
decrease_NN
in_PIN
short_JJ
term_NN
investments_NOMZ
1,855_CD
617_CD
Change_NN
in_PIN
net_JJ
funds_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
444_CD
430_CD
Exchange_NN
movements_NOMZ
cash_NN
and_PHC
debt_NN
34_CD
82_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
UK_NN
GAAP_NN
478_CD
348_CD
Fair_NN
value_NN
adjustments_NOMZ
180_CD
13_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
298_CD
361_CD
